Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
OTLK
OTLK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OTLK News
Outlook Therapeutics Requests FDA Meeting Following CRL for ONS-5010
5d ago
Newsfilter
U.S. Stocks Close Higher on Friday, Nasdaq Slightly Declines, Market Sentiment Neutral
Jan 05 2026
Benzinga
Health Care Stocks Mixed as NYSE Health Care Index Edges Up
Jan 02 2026
Yahoo Finance
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
Jan 02 2026
Benzinga
ChowChow Cloud Reports 29% Revenue Growth in H1 2025
Jan 02 2026
Benzinga
Baidu Inc. Proposes Spinoff of Kunlunxin, Shares Rise 11%
Jan 02 2026
Benzinga
Outlook Therapeutics Faces 60.82% Drop After FDA Rejects Lytenava Application
Jan 02 2026
Benzinga
Outlook Therapeutics Inc Faces 60.9% Drop After FDA Response on ONS-5010
Jan 02 2026
Benzinga
ARS Pharma's Neffy Approved in China for Allergy Treatment
Jan 02 2026
NASDAQ.COM
Baidu Inc. Proposes Spinoff of Kunlunxin H Shares, Stock Jumps 12.20%
Jan 02 2026
Benzinga
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
Jan 02 2026
Benzinga
Apple Inc. Scales Back Vision Pro Production Amid Sales Struggles
Jan 02 2026
Benzinga
Outlook Therapeutics Faces FDA Rejection for ONS-5010 Biologics License Application
Jan 01 2026
Yahoo Finance
Outlook Therapeutics Faces 63.29% Stock Drop After FDA Rejects ONS-5010 Approval Again
Jan 01 2026
NASDAQ.COM
Outlook Therapeutics Faces FDA Complete Response for ONS-5010 Application
Dec 31 2025
Globenewswire
Outlook Therapeutics Faces FDA Complete Response on ONS-5010 Application
Dec 31 2025
Newsfilter
Show More News
